Recent clinical efforts, such as the SKYSCRAPER-01 trial combining PDL1 blockade with an anti-TIGIT Ab, have failed to lead to improved responses in lung cancer, and there is a need to better understand the mechanisms of immune evasion in order to design rational combination strategies that are more likely to provide clinical benefit. The gene discussed is CD274; the disease is lung carcinoma.